Fig. 7

Targeting FTO reduces GH secreting capability of tumor cells and enhances their sensitivity to somatostatin analogs. a. Bar plots showing the Sstr2 and Gh1 level change after Fto knockdown through RNA-seq analysis. b. Bar plots showing the Sstr2 and Gh1 level change after FTO and DSP knockdown in GH3 cells (left) and primary tumor cells (right) through qPCR analysis under the stimulation of octreotide (100nM). c. Bar plots showing the growth hormone level changes following FTO and DSP knockdown in GH3 cells (left) and primary tumor cells (right) under the stimulation of octreotide (100nM). d. Electron microscopy showing fewer secretory granules after FTO knockdown in primary tumor cells. e. Bar plots showing the octreotide sensitivity change after FTO knockdown in GH3 cells (left) and primary tumor cells (right). f. Bar plots showing the octreotide sensitivity change after combing with FB23-2 treatment in GH3 cells (left) and primary tumor cells (right). g. Bar plots showing the growth hormone level changes following octreotide and FB23-2 treatment in GH3 cells (left) and primary tumor cells (right). h. Bar plots showing the octreotide sensitivity (left) and growth hormone level (right) change after combining with FB23-2 in organoids. i-j. In vivo assessment of octreotide sensitivity in GH3 xenografts by injecting with or without Fto knockdown GH3 cells according to tumor volume (j), tumor weight (k) and growth hormone level (l). Each experiment was replicated independently at least three times